GSK PLC

GSK stock climbs 2.5% amid UK pharma rally, boasting higher‑than‑inflation dividends and solid clinical data, making it a compelling income and growth option.

GSK shares rise on new China partnership to develop KRAS‑targeted ADC, boosting its oncology pipeline and future revenue potential.

Explore how GSK’s 8‑year Varaha partnership for 500k+ carbon credits and executive share‑reward plans strengthen ESG and investor confidence.

GSK’s Japan approval of Shingrix’s prefilled‑syringe boosts vaccine uptake and investor confidence, highlighting streamlined delivery, executive alignment, and global growth.

GSK plc’s new U.S. IPO filing under Regulation 424(b)(2) highlights a strategic move to raise capital—potentially $200‑$400 m—to fuel R&D, pay down debt, and strengthen its pharma position. This preview offers investors insight into the company’s gr…

GSK partners with Hutchmed to accelerate HMPL‑A830, a first‑in‑class KRAS‑EGFR antibody‑drug conjugate, aiming for a $5 billion+ oncology market and enhanced patient value.

GSK PLC nears its 52‑week peak as shareholders ratify strong governance and dividends, signalling solid growth prospects and steady investor returns.

GSK plc’s August ADS sales on the NYSE unlock liquidity for its high‑impact biologics and oncology pipeline, fueling drug development while meeting SEC‑filed compliance.

GSK’s tax refund, director share buy, and new compliance board seat boost liquidity, governance, and readiness for value‑based pharma markets.

GSK plc’s recent 6‑K filing discloses a routine purchase of 9,000 American Depositary Shares by US President Maya Martinez‑Davis, confirming the company’s compliance with SEC rules and illustrating stable insider activity amid global market volatili…